Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy

  • Technology appraisal guidance
  • TA962
  • Published: 

Evidence

Supporting evidence